Cole G Bradley 4

What Happened

• Cole G. Bradley, a director of Kiniksa Pharmaceuticals International, plc (KNSA), received equity awards and executed an option/derivative conversion on May 29, 2026. The filing shows grants of 12,158 RSUs and 2,026 RSUs (total 14,184 RSUs) at $0.00 and an exercise/conversion of 2,799 derivative shares. The filing also reports a contemporaneous disposition of 2,799 shares related to the exercise; no cash values were reported for these transactions.
• These entries represent compensation awards (RSUs) and an option/derivative exercise rather than an open‑market purchase. The RSUs are awarded at $0 and therefore reflect compensation, not a paid acquisition.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (appears timely).
• Grants: 12,158 RSUs @ $0.00 and 2,026 RSUs @ $0.00 (each RSU = right to one Class A ordinary share).
• Exercise/conversion: 2,799 derivative shares exercised/converted; same number (2,799) reported as disposed (both reported with $0 cash consideration).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Relevant footnotes:
  • F1: Each RSU entitles holder to one Class A ordinary share on settlement.
  • F2: Option vesting schedule noted (monthly over ~12 months; grant date May 29, 2026).
  • F3/F4: RSUs vest in full on the earlier of one year or the next annual meeting; here RSUs vested in a single installment on May 29, 2026.

Context

• The combination of an exercise/conversion and an immediate disposal of the same number of shares is commonly consistent with share withholding for taxes or a cashless exercise, though the filing does not state the reason.
• These transactions are primarily compensation-related (awarded RSUs and exercised derivatives) and do not represent an open-market buy signal.